Log in

NASDAQ:ZYNEZynerba Pharmaceuticals Stock Price, Forecast & News

$3.84
+0.09 (+2.40 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.70
Now: $3.84
$3.89
50-Day Range
$3.25
MA: $4.34
$6.54
52-Week Range
$2.55
Now: $3.84
$12.51
Volume671,045 shs
Average Volume1.11 million shs
Market Capitalization$95.81 million
P/E RatioN/A
Dividend YieldN/A
Beta3.08
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Read More
Zynerba Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$3.26 per share

Profitability

Net Income$-32,940,000.00

Miscellaneous

Employees25
Market Cap$95.81 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable
$3.84
+0.09 (+2.40 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

How has Zynerba Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYNE shares have decreased by 1.3% and is now trading at $3.84.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Zynerba Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zynerba Pharmaceuticals
.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Zynerba Pharmaceuticals
.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.03.
View Zynerba Pharmaceuticals' earnings history
.

What price target have analysts set for ZYNE?

7 analysts have issued 12 month price targets for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.00 to $26.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $13.86 in the next year. This suggests a possible upside of 260.9% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals
.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (5/30/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We understand the market’s reaction when focusing on a few items: 1) There was a case of status epilepticus (SE); 2) 96% of patients reported an adverse event (AE); 3) 10/48 (21%) reported a serious adverse event (SAE); 4) Zygel doesn’t work fast enough; 5) 7 of 48 (15%) dropped out for efficacy; and 6) There were only 11 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) patients. However, we find some perspective on these figures are important to consider: 1. SE has not been found in any previous Zygel trial, including the Phase 2s in adult refractory epilepsy (n=188), osteoarthritis of the knee (n=300) and Fragile X syndrome (FXS; n=16). As we have described in our notes on Buy), SE typically occurs in patients highly compromised by underlying health conditions and/or trauma." (9/18/2019)

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

News coverage about ZYNE stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynerba Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Zynerba Pharmaceuticals
.

Who are some of Zynerba Pharmaceuticals' key competitors?

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)
  • Ms. Terri B. Sebree, Pres (Age 61)
  • Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)
  • Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Zeke Capital Advisors LLC (1.77%), AdvisorShares Investments LLC (1.53%), Nisa Investment Advisors LLC (0.08%) and Davy Global Fund Management Ltd (0.05%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler and Terri B Sebree.
View institutional ownership trends for Zynerba Pharmaceuticals
.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was acquired by a variety of institutional investors in the last quarter, including Zeke Capital Advisors LLC, AdvisorShares Investments LLC, Nisa Investment Advisors LLC, and Davy Global Fund Management Ltd. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, and Terri B Sebree.
View insider buying and selling activity for Zynerba Pharmaceuticals
.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $3.84.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $95.81 million and generates $90,000.00 in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.